A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Combination With Pembrolizumab or Binimetinib in Adult Patients With Advanced Solid Tumors
What is the purpose of this trial?
To evaluate the safety and tolerability of JAB-3312 administered in investigational regimens in adult participants with advanced solid tumors.
- Trial withJacobio Pharmaceuticals Co., Ltd
- Start Date06/08/2021
- End Date09/30/2022
- Last Updated07/15/2021
- Study HIC#2000029875